Increasing sales of the HIV drug Fuzeon helped Trimeris (Nasdaq: TRMS) cut its quarterly losses.
Trimeris said it posted a net profit of $2.2 million in Fuzeon sales along with partner Roche. The second-straight quarterly profit boosted Trimeris to a net of $3.5 million in Fuzeon sales for the first nine months of the year.
Overall, Trimeris still lost money – $3.3 million, or 15 cents a share. That’s down from $8.3 million, or 38 cents, in 2004.